Henlius HLX10-020-SCLC302
Trial Overview
Official Title
Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Study Purpose
To evaluate the effectiveness of HLX10 in combination with chemotherapy and radiation.
Diagnosis
Limited stage small cell lung cancer (LS-SCLC)Eligibility
Unresectable stage I-III patients able to be safely treated with curative radiation.
Intervention
Experimental arm: HLX10 plus chemotherapy (carboplatin or cisplatin and etoposite) plus radiation
Control arm: placebo plus chemotherapy (carboplatin or cisplatin and etoposite) plus radiation
For more information, click the link below:
https://clinicaltrials.gov/study/NCT05353257?term=HLX10-020-SCLC302&rank=1